These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8061425)
21. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. Mori K; Yoshioka H; Itai Y; Okamoto Y; Mori H; Takahashi N; Saida Y AJR Am J Roentgenol; 2000 Dec; 175(6):1659-64. PubMed ID: 11090400 [TBL] [Abstract][Full Text] [Related]
23. Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. Small WC; Nelson RC; Bernardino ME Magn Reson Imaging; 1993; 11(5):645-54. PubMed ID: 8345779 [TBL] [Abstract][Full Text] [Related]
24. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047 [TBL] [Abstract][Full Text] [Related]
25. T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. Chen RC; Lii JM; Chou CT; Chang TA; Chen WT; Li CS; Tu HY J Formos Med Assoc; 2008 Oct; 107(10):798-805. PubMed ID: 18926947 [TBL] [Abstract][Full Text] [Related]
26. Decrease of signal intensity of myometrium and cervical stroma after ultrasmall superparamagnetic iron oxide (USPIO) particles administration: an MR finding with potential benefits in T staging of uterine neoplasms. Laghi A; Paolantonio P; Panebianco V; Miglio C; Iafrate F; Di Tondo U; Passariello R Invest Radiol; 2004 Nov; 39(11):666-70. PubMed ID: 15486527 [TBL] [Abstract][Full Text] [Related]
27. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Mack MG; Balzer JO; Straub R; Eichler K; Vogl TJ Radiology; 2002 Jan; 222(1):239-44. PubMed ID: 11756732 [TBL] [Abstract][Full Text] [Related]
28. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Tanimoto A; Yuasa Y; Shinmoto H; Jinzaki M; Imai Y; Okuda S; Kuribayashi S Radiology; 2002 Mar; 222(3):661-6. PubMed ID: 11867782 [TBL] [Abstract][Full Text] [Related]
29. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254 [TBL] [Abstract][Full Text] [Related]
30. Preliminary results of MR imaging with superparamagnetic iron oxide in pancreatic and retroperitoneal disorders. Torres GM; Erquiaga E; Ros PR; Burton SS; Barreda R; Langmo LS; Kennedy SJ Radiographics; 1991 Sep; 11(5):785-91; discussion 792-3. PubMed ID: 1947314 [TBL] [Abstract][Full Text] [Related]
31. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions. Mergo PJ; Helmberger T; Nicolas AI; Ros PR AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952 [TBL] [Abstract][Full Text] [Related]
32. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer. Nolte-Ernsting C; Adam G; Bücker A; Berges S; Bjørnerud A; Günther RW AJR Am J Roentgenol; 1998 Jul; 171(1):107-13. PubMed ID: 9648772 [TBL] [Abstract][Full Text] [Related]
33. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research. Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684 [TBL] [Abstract][Full Text] [Related]
34. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. Guimaraes R; Clément O; Bittoun J; Carnot F; Frija G AJR Am J Roentgenol; 1994 Jan; 162(1):201-7. PubMed ID: 8273666 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of superparamagnetic iron oxide for MR imaging of liver injury: proton relaxation mechanisms and optimal MR imaging parameters. Tanimoto A; Mukai M; Kuribayashi S Magn Reson Med Sci; 2006 Jul; 5(2):89-98. PubMed ID: 17008765 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the changes in signals from the spleen using ferucarbotran. Gomi T; Nagamoto M; Tsunoo M; Terada S; Terada H; Kohda E Radiat Med; 2007 Apr; 25(3):135-8. PubMed ID: 17450339 [TBL] [Abstract][Full Text] [Related]
37. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging. Lee JM; Kim CS; Youk JH; Lee MS Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629 [TBL] [Abstract][Full Text] [Related]
38. MR contrast agents in acute experimental cerebral ischemia: potential adverse impacts on neurologic outcome and infarction size. Doerfler A; Engelhorn T; Heiland S; Knauth M; Wanke I; Forsting M J Magn Reson Imaging; 2000 Apr; 11(4):418-24. PubMed ID: 10767071 [TBL] [Abstract][Full Text] [Related]